SciSparc Ltd Dossier
Qualitative Analysis
Business overview
SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) is a specialty clinical-stage pharmaceutical company headquartered in Tel Aviv, Israel. The company is dedicated to creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. SciSparc's drug development programs focus on central nervous system (CNS) disorders and pain management. Its primary clinical pipeline includes SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation, SCI-210 for autism spectrum disorder and status epilepticus, and CannAmide, an anti-inflammatory and chronic pain solution. The company operates through two primary segments: Drug Development (focused on cannabinoid molecules) and Online Sales (hemp seed oil-based products).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
An initiative launched by the board of directors to integrate quantum computing algorithms into 3D protein modeling to transform drug discovery, achieve high accuracy in predicting protein structures, and model protein-ligand interactions.
Expected impact: Aims to create new intellectual property and accelerate the discovery of novel drug candidates by simulating protein energy dynamics with high precision.
Strategic plan to commercialize the newly acquired MUSE™ single-use endoscopic device for transoral fundoplication to treat gastroesophageal reflux disease (GERD).
Expected impact: Replicate Xylo's successful Greater China licensing model in North America, Europe, and Latin America by pursuing exclusive partnerships with regional distributors to unlock new revenue streams.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of a 54% controlling interest in CliniQuantum by SciSparc's subsidiary NeuroThera Labs Inc. to integrate quantum simulation and quantum Monte Carlo methods into clinical trial data analysis, enhancing precision in identifying patient subpopulations.
Financial impact: Adds contingent liabilities of up to USD 2.5 million in milestone-based earn-out payments, while expanding NeuroThera's technology and IP footprint.
Acquisition of a comprehensive IP portfolio of patents, trademarks, and know-how associated with the MUSE™ single-use endoscopic system and medical cameras to target the global multi-billion dollar GERD device market.
Financial impact: Expands SciSparc's medical device IP footprint and sets the stage for immediate commercialization and distribution partnerships.
Strategic Partnerships
Ongoing collaboration since 2022 to develop innovative proprietary combination therapies combining Clearmind's psychedelic molecules (like MEAI) with SciSparc's cannabinoid-based compounds (like Palmitoylethanolamide/PEA) to treat addictions, obesity, depression, and binge behavior disorders.
Terms: Jointly funded studies and IP development, resulting in the filing of 13 patent families across multiple jurisdictions including the US, Europe, and China.